SCHEMBL14872113

SCHEMBL14872113

COC(=O)[C@H](CO)NCCl

nearest known ligand 0.39

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MME P08473 2/20 0.39
TGFBR1 P36897 2/20 0.38
CYP2C9 P11712 2/20 0.35
ALDH1A1 P00352 1/20 0.35
THRB P10828 1/20 0.35
CYP2C19 P33261 1/20 0.35
HSD17B10 Q99714 1/20 0.35
SMN1; SMN2 Q16637 2/20 0.34
PDCD1 Q15116 4/20 0.34
CD274 Q9NZQ7 4/20 0.34
MEN1 O00255 1/20 0.32
TSHR P16473 1/20 0.32
KMT2A Q03164 1/20 0.32
CA1 P00915 1/20 0.31
CA2 P00918 1/20 0.31
FOLH1 Q04609 1/20 0.31
CA14 Q9ULX7 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8245351 0.82 TGFBR1 (0.41) MMETGFBR1CYP2C9ALDH1A1THRB
SCHEMBL23375007 0.80 MME (0.40) MMETGFBR1CYP2C9ALDH1A1THRB
SCHEMBL21309845 0.80 MME (0.40) MMETGFBR1CYP2C9ALDH1A1THRB
SCHEMBL23374703 0.80 MME (0.40) MMETGFBR1CYP2C9ALDH1A1THRB
SCHEMBL14337375 0.79 MME (0.37) MMETGFBR1CYP2C9ALDH1A1THRB
SCHEMBL14872110 0.79 FOLH1 (0.45) MMECYP2C9CYP2C19SMN1; SMN2FOLH1
SCHEMBL14872123 0.79 KMT2A (0.33) MMESMN1; SMN2KMT2ACA2FOLH1
SCHEMBL14872114 0.78 FOLH1 (0.38) ALDH1A1SMN1; SMN2FOLH1CA14
SCHEMBL13071367 0.77
SCHEMBL13071368 0.77

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130096090-A1 TRANSITION METAL COMPLEXES OF AMINO ACIDS AND RELATED LIGANDS AND THEIR USE AS CATALYSTS, ANTI-MICROBIALS, AND ANTI-CANCER AGENTS VIRGINIA TECH INTELLECTUAL PROPERTIES, INC. (US) 2013-04-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130096090-A1 TRANSITION METAL COMPLEXES OF AMINO ACIDS AND RELATED LIGANDS AND THEIR USE AS CATALYSTS, ANTI-MICROBIALS, AND ANTI-CANCER AGENTS MCL1, GLS, ERAL1 MME 1274/4885TGFBR1 3279/4885CYP2C9 4002/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.